ALK and non-small cell lung carcinoma: In order to identify an enriched population of patients with NSCLC harboring EML4-ALK fusion gene and to identify more useful information on candidate selection for ALK tyrosine kinase inhibitor therapy, we performed this meta-analysis to compare the frequency of the EML4-ALK fusion gene in patients with different clinicopathologic features.